AU2009279090A1 - Conjugated proteins with prolonged in vivo efficacy - Google Patents

Conjugated proteins with prolonged in vivo efficacy Download PDF

Info

Publication number
AU2009279090A1
AU2009279090A1 AU2009279090A AU2009279090A AU2009279090A1 AU 2009279090 A1 AU2009279090 A1 AU 2009279090A1 AU 2009279090 A AU2009279090 A AU 2009279090A AU 2009279090 A AU2009279090 A AU 2009279090A AU 2009279090 A1 AU2009279090 A1 AU 2009279090A1
Authority
AU
Australia
Prior art keywords
protein
pct
hgh
albumin
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2009279090A
Other languages
English (en)
Inventor
Henrik Sune Andersen
Sonja Bak
Carsten Behrens
Patrick William Garibay
Nils Langeland Johansen
Soren Ostergaard
Bernd Peschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Publication of AU2009279090A1 publication Critical patent/AU2009279090A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2009279090A 2008-08-06 2009-08-06 Conjugated proteins with prolonged in vivo efficacy Withdrawn AU2009279090A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08161905 2008-08-06
EP08161905.8 2008-08-06
PCT/EP2009/060186 WO2010015668A1 (en) 2008-08-06 2009-08-06 Conjugated proteins with prolonged in vivo efficacy

Publications (1)

Publication Number Publication Date
AU2009279090A1 true AU2009279090A1 (en) 2010-02-11

Family

ID=41334423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009279090A Withdrawn AU2009279090A1 (en) 2008-08-06 2009-08-06 Conjugated proteins with prolonged in vivo efficacy

Country Status (11)

Country Link
US (1) US8865868B2 (enExample)
EP (1) EP2323694A1 (enExample)
JP (1) JP5977945B2 (enExample)
KR (1) KR20110039348A (enExample)
CN (1) CN102112157B (enExample)
AU (1) AU2009279090A1 (enExample)
BR (1) BRPI0917000A2 (enExample)
CA (1) CA2733200A1 (enExample)
MX (1) MX2011000847A (enExample)
RU (1) RU2526804C2 (enExample)
WO (1) WO2010015668A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
BRPI0922344A2 (pt) 2008-12-19 2017-10-24 3B Pharmaceuticals Gmbh inibidores de tfpi e métodos de uso
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
CN118767115A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
EP2536434B1 (en) * 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
WO2012010516A1 (en) * 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
RU2013142015A (ru) 2011-03-02 2015-04-10 Ново Нордиск А/С Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
EA028578B1 (ru) * 2012-02-14 2017-12-29 Опко Байолоджикс Лтд. Факторы свертывания крови пролонгированного действия и способы их получения
CN104302306B (zh) 2012-03-21 2019-03-22 百深有限责任公司 Tfpi抑制剂及其使用方法
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
ES2629735T3 (es) * 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
EP2922867B1 (en) 2012-11-20 2021-07-21 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
FR3006315B1 (fr) * 2013-05-31 2015-10-02 Centre Nat Rech Scient Microparticules et nanoparticules auto-associatives composees de proteines
FR3011470B1 (fr) 2013-10-09 2017-01-06 Centre Nat De La Rech Scient (Cnrs) Composition antifongique comprenant un agent antifongique et du chitosane hydrophobise
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10583104B2 (en) 2014-08-06 2020-03-10 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
PH12017501089B1 (en) 2014-12-10 2022-06-22 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
CA2972871A1 (en) * 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
AU2016280867B2 (en) 2015-06-19 2020-02-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
KR102618424B1 (ko) 2016-07-11 2023-12-26 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
US20240317832A1 (en) * 2021-07-29 2024-09-26 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate
CN113698468B (zh) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
ES2154627T3 (es) 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
DE68929151T2 (de) 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
EP0555649B1 (en) 1992-01-14 2004-12-08 Ajinomoto Co., Inc. Gene encoding transglutaminase derived from fish
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JP3758187B2 (ja) 1994-01-28 2006-03-22 味の素株式会社 マガキ由来のトランスグルタミナーゼ
WO1996006931A1 (en) 1994-08-26 1996-03-07 Novo Nordisk A/S Microbial transglutaminases, their production and use
CN1165539A (zh) 1994-09-29 1997-11-19 味之素株式会社 肽及蛋白质的修饰
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
DE69629719T2 (de) 1995-01-19 2004-07-08 Novozymes A/S Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CA2658039A1 (en) 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2000517308A (ja) 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―２誘導体
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
RU2214418C2 (ru) 1998-12-07 2003-10-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги glp-1
CN1191273C (zh) 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003519664A (ja) 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
JP2005525302A (ja) 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
NZ535684A (en) 2002-04-10 2006-03-31 Lilly Co Eli Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying
CN101942019A (zh) 2002-04-30 2011-01-12 拜耳医药保健有限公司 凝血因子VII或VIIa多肽变体
ATE466085T1 (de) 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
JP2006516034A (ja) 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
CA2513307A1 (en) 2003-02-19 2004-09-02 Zheng Xin Dong Analogues of glp-1
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
EP1673464A2 (en) 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
KR20060135661A (ko) 2003-12-18 2006-12-29 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 화합물
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
JP2006273834A (ja) 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
EP1762234A4 (en) 2004-06-28 2010-05-05 Kao Corp AMPK AKTIVATOR
EP1765408B1 (en) 2004-07-08 2015-12-09 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
JP2008507990A (ja) * 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
US20080274075A1 (en) 2005-05-20 2008-11-06 Novo Nordisk Healthcare A/G Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20090041744A1 (en) 2005-06-17 2009-02-12 Novo Nordisk Healthcare A/G Dimeric and Multimeric FVIIa Compounds
EP1919946A1 (en) 2005-08-18 2008-05-14 Novo Nordisk Health Care AG Transglutaminase variants with improved specificity
US20090082254A1 (en) 2006-02-14 2009-03-26 Novo Nordisk A/S Coupling of Polypeptides at the C-Terminus
CA2655188A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CA2672267C (en) 2006-07-27 2016-05-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
JP2010500885A (ja) 2006-08-18 2010-01-14 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
PL2059260T3 (pl) 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
EP2129218B1 (en) 2007-02-16 2016-10-19 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
ES2532116T3 (es) * 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii

Also Published As

Publication number Publication date
US8865868B2 (en) 2014-10-21
CN102112157A (zh) 2011-06-29
KR20110039348A (ko) 2011-04-15
JP2011529948A (ja) 2011-12-15
BRPI0917000A2 (pt) 2016-02-16
EP2323694A1 (en) 2011-05-25
CN102112157B (zh) 2013-05-29
RU2526804C2 (ru) 2014-08-27
US20110223151A1 (en) 2011-09-15
JP5977945B2 (ja) 2016-08-24
RU2011106573A (ru) 2012-09-20
WO2010015668A1 (en) 2010-02-11
MX2011000847A (es) 2011-02-25
CA2733200A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
US8865868B2 (en) Conjugated proteins with prolonged in vivo efficacy
EP2461831B1 (en) Growth hormones with prolonged in-vivo efficacy
RU2385879C2 (ru) Способ конъюгации пептидов, опосредованной трансглутаминазой
CA2787890C (en) Growth hormones with prolonged in-vivo efficacy
EP2289560B1 (en) Polypeptide protracting tags comprising a tetrazole moiety
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
JP2008543297A (ja) トランスグルタミナーゼを介した成長ホルモンのコンジュゲート
ES2703388T3 (es) Hormonas de crecimiento con eficacia prolongada in vivo
ES2745484T3 (es) Hormonas de crecimiento con eficacia prolongada in vivo
AU2013204527A1 (en) Growth hormones with prolonged in-vivo efficacy
JP2008545644A (ja) 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法
KR20070017494A (ko) 펩티드의 트랜스글루타미나아제 매개된 접합

Legal Events

Date Code Title Description
MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal